Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidil and caffeine are discussed for hair loss treatment. The user questions the logic of combining them due to their opposing effects on adenosine receptors.

Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.

The conversation discusses the effectiveness of Vichy Dercos Aminexil Clinical R.E.G.E.N. Booster for hair shedding and thinning. The main ingredient, Aminexil, is compared to Minoxidil, and the user seeks real experiences to determine its efficacy.

The conversation discusses hair loss treatments, specifically asking about clinics in the US that perform dutasteride mesotherapy. Minoxidil, finasteride, and RU58841 are also mentioned.

User experienced feminizing side effects from finasteride and tried RU, alfatradiol, and finasteride without success. They are now considering treatments like Stemoxydine, Zix, Minoxidil, Dermarolling, Eucapil, and a hair transplant.

A person mistakenly drank an entire bottle of topical minoxidil, leading to ICU admission with shock and heart failure. The incident highlights the dangers of ingesting topical treatments and the importance of proper usage and dosage.

The conversation discusses using Shatavari, an Ayurvedic treatment, for hair loss. Other treatments mentioned include Minoxidil, finasteride, and RU58841.

The user discusses using Minoxidil for hair loss and is considering RU58841 to reduce excessive oil production. They seek advice on RU58841's effectiveness in blocking sebum production.

Redensyl improved hair thickness slightly with no side effects, but no regrowth. Minoxidil provided significant regrowth but caused facial side effects like puffiness.

RU and Pyri block androgen receptors to prevent hair loss but may also hinder hair regrowth since they prevent testosterone, which can stimulate hair growth, from binding to these receptors. The user is questioning if this understanding is correct.

Clascoterone and RU58841 are compared for effectiveness in treating hair loss. The discussion involves treatments like Minoxidil, finasteride, and RU58841.

User is seeking information on obtaining dutasteride vials for mesotherapy in the US, mentioning a closed source and lack of local clinic options.

Late 20s woman struggles with worsening hair loss and tried various treatments without success. Now trying spironolactone and ketokonazole shampoo, hoping for improvement.

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

The conversation discusses hair loss treatments, including dutasteride, oral minoxidil, finasteride, and potential additions like topical finasteride, minoxidil, micro-needling, and topical anti-androgens such as RU58841. The effectiveness and worth of these treatments, including localized dutasteride mesotherapy, are considered.

RU58841 and Minoxidil can cause heart-related side effects like chest pain and heart racing. Pyrilutamide is suggested as a safer alternative, though it's new and costly.

A 27-year-old male experiencing hair loss post-Covid is considering PRP (platelet-rich plasma) therapy. He's seeking personal experiences about the process, particularly regarding pain levels, despite his dermatologist's assurance of using local anesthesia.

The user discusses using Follics FR5, FR10, and FR15, which combine Minoxidil, Adenosine, Procapil, Azelaic acid, and Procyanidin B2, to address hair loss. They have previously used Minoxidil, Finasteride, and Dutasteride with varying success.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

A 48-year-old male is experiencing hair loss despite taking finasteride for four months. He is considering oral minoxidil but is concerned about high blood pressure and is unsure about taking spironolactone.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

Scalp Botox may help hair loss by relaxing muscles and increasing blood flow, potentially benefiting conditions other than androgenetic alopecia. DHT affects hair follicles differently, causing tension and hair loss in some areas but not others.

A 17-year-old with AGA is considering Revitacare Haircare Mesotherapy, which includes hyaluronic acid, amino acids, zinc, and B vitamins, injected into the scalp. One reply dismisses it as ineffective.

The conversation is about managing hair loss while on hormone replacement therapy (HRT) with estrogen and spironolactone. The user considers adding finasteride but decides to wait and see the effects of the current treatment.

A 24-year-old experiencing severe hair thinning has been using minoxidil for 2 years but is still shedding hair. A doctor recommended plasma treatment over a DHT blocker for better and healthier results.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The conversation discusses switching from topical to oral Minoxidil for hair loss treatment, with the expectation of better results due to systemic delivery. The user has been using Finasteride, topical Minoxidil, and dermastamping, maintaining hair but seeking more regrowth.

Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.

Copper peptides are discussed as a potential alternative to minoxidil for treating hair loss. Users share interest and challenges in accessing copper peptides, with some mentioning specific products.